Skip to Main Content

Paper Details

TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
J Clin Oncol
62
2021
Androgen, BAT, CRPC, Castration-Resistant Metastatic Prostate Cancer, Enzalutamide, Men, PCa, PSA, PSA50, Patient, Prostate cancer, Testosterone, androgen, androgen receptor, castration-resistant PCa, enzalutamide, enzalutamideBAT, men, patients, prostate-specific antigen, testosterone
Author NameAffiliation
Neeraj AgarwalThe Huntsman Cancer Institute
David C SmithThe University of Michigan ann arbor
Oliver SartorTulane University
Channing J PallerThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Michael A CarducciThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mark C MarkowskiThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mario A EisenbergerThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Emmanuel S AntonarakisThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • 1 - 8

Datasets

Release 1.2